Cue Biopharma (NASDAQ:CUE) Stock: Insider Shao-Lee Lin Sells 11,087 Shares

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 11,087 shares of Cue Biopharma stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $27.55, for a total transaction of $305,446.85. Following the sale, the chief executive officer owned 694,908 shares of the company’s stock, valued at approximately $19,144,715.40. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The shares were sold at an average price of $28.62, for a total transaction of $522,543.96.
• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Price Performance

Shares of CUE opened at $18.67 on Friday. The company’s 50 day simple moving average is $27.57 and its 200 day simple moving average is $70.86. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The firm had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%. Sell-side analysts predict that Cue Biopharma, Inc. will post -21.79 earnings per share for the current year.

Institutional Investors Weigh In On Cue Biopharma

Several institutional investors have recently bought and sold shares of CUE. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Cue Biopharma in the second quarter worth $83,000. Bank of America Corp DE purchased a new position in shares of Cue Biopharma in the 2nd quarter valued at $219,000. Seven Fleet Capital Management LP acquired a new position in shares of Cue Biopharma during the 2nd quarter valued at $338,000. Persistent Asset Partners Ltd acquired a new position in shares of Cue Biopharma during the 2nd quarter valued at $389,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Cue Biopharma during the 2nd quarter valued at $722,000. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Wall Street Zen downgraded Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. Zacks Research upgraded Cue Biopharma to a “hold” rating in a research note on Monday, September 21st. B. Riley Financial initiated coverage on Cue Biopharma in a research report on Friday, September 18th. They set a “buy” rating and a $83.00 target price on the stock. Finally, Weiss Ratings downgraded Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $83.00.

Cue Biopharma Company Profile

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.